COSCIENS Biopharma Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Revenue | $923.0K | $911.0K | $545.0K |
| Cost of Revenue | $0 | $0 | — |
| Gross Profit | $923.0K | $911.0K | — |
| Gross Margin | 100.0% | 100.0% | — |
| Operating Expenses | |||
| Research & Development | — | — | — |
| SG&A Expense | — | — | — |
| Operating Income | $-23.1M | $-29.5M | $-34.9M |
| Operating Margin | -2,499.9% | -3,235.6% | -6,400.7% |
| Interest Expense | — | — | — |
| Pretax Income | $-20.3M | $-25.0M | $-50.2M |
| Income Tax Expense | $-3.5M | $0 | $0 |
| Net Income | $-16.8M | $-25.0M | $-50.1M |
| Net Margin | -1,819.7% | -2,739.7% | -9,200.6% |
| EPS (Basic) | $-1.12 | $-2.41 | — |
| EPS (Diluted) | $-1.12 | $-2.41 | — |
| Shares Outstanding (Basic) | 16.4M | — | — |
| Shares Outstanding (Diluted) | 16.4M | — | — |
| Dividends Per Share | — | — | — |